Program Description
As a complex, chronic disease, obesity requires lifelong management. Because weight regain and metabolic complications frequently follow treatment discontinuation, ongoing strategies are essential to support long-term patient success. This webinar highlights approaches for pharmacists to address the pathophysiology and clinical burden of obesity. Faculty will synthesize key concepts from “The Educated Pharmacist—Weighing In” curriculum, guiding participants to apply current guidelines and clinical evidence when selecting appropriate candidates for glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonist therapy based on obesity severity, cardiorenal-metabolic comorbidities, and patient-specific factors. Learners will explore how to develop individualized treatment plans incorporating precise medication selection, dose titration, administration techniques, adverse effect management, and nonpharmacologic interventions. The discussion will explore practical methods to overcome patient-, provider-, and system-level barriers to long-term obesity therapy persistence. Through a faculty-led patient case discussion, participants will examine real-world approaches to implement pharmacist-led strategies that enhance treatment initiation, persistence, and adherence through patient-centered counseling, motivational interviewing, and structured follow-up.
Target audience: Community pharmacists
Type of activity: Application
Release date: October 9, 2026
Expiration date: October 9, 2027
Learner level: Intermediate
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology and clinical burden of obesity and the impact of clinical inertia on the initiation and optimization of evidence-based treatment
- Apply current guidelines and clinical evidence to identify appropriate candidates for GLP-1 receptor agonist and dual GIP/GLP-1 receptor agonist therapy based on obesity severity, cardiorenal-metabolic comorbidities, expected benefits, safety considerations, and patient-specific factors
- Explore individualized treatment plans that incorporate medication selection, dose titration, administration technique, adverse effect mitigation and management, and nonpharmacologic interventions
- Identify pharmacist-led strategies to address barriers to treatment initiation, persistence, and long-term adherence through patient-centered counseling, motivational interviewing, and follow-up
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice/Director of Cardiometabolic Services
Massachusetts College of Pharmacy and Health Sciences/Well Life Medical
Boston, MA
Heather Whitley, PharmD, BCPS, CDCES, FCCP
Clinical Professor of Pharmacy Practice
Auburn University Harrison College of Pharmacy
Montgomery, AL
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.5 contact hours (0.15 CEUs) under the ACPE universal activity number 0290-0000-26-318-H01-P. The activity is available for CE credit through October 9, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Faculty
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose:
Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris
The following contributors have no relevant financial relationships with ineligible companies to disclose:
Faculty
Heather Whitley, PharmD, BCPS, CDCES, FCCP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Dipti Desai, PharmD, MBA, CHCP; Emily Tyler; and Brianna Winters.
Any relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms
